Search results for "Thiomer"

showing 3 items of 3 documents

Piroxicam-induced photosensitivity and contact sensitivity to thiosalicylic acid

1990

A photocontact dermatitis developed in three patients after the application of gel containing 0.5% piroxicam. Patch tests were positive to thiomersal and thiosalicylic acid. Photopatch tests with piroxicam at several concentrations were positive in the three patients but negative in 62 normal volunteer subjects. Patch tests performed on 14 patients with proved systemic photosensitivity to piroxicam were positive for thiomersal and thiosalicylic acid. Nine of 12 patients previously sensitized to thiosalicylic acid and with no history of exposure to piroxicam showed positive photopatch test reactions to this chemical. These results support a relation between piroxicam-induced photosensitivity…

AdultMaleThiosalicylic acidmedicine.medical_specialtyDermatologyPiroxicamDermatitis ContactBenzoateschemistry.chemical_compoundPiroxicamPhotosensitivityMedicineHumansPhotosensitivity DisordersSulfhydryl CompoundsVolunteerbusiness.industryThimerosalPhotosensitivity reactionsPhotocontact DermatitisMiddle AgedPatch TestsContact sensitivityDermatologychemistryFemaleThiomersalbusinessGelsmedicine.drug
researchProduct

Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines

2009

OBJECTIVE. Thimerosal, a mercury compound used as a preservative in vaccines administered during infancy, has been suspected to affect neuropsychological development. We compared the neuropsychological performance, 10 years after vaccination, of 2 groups of children exposed randomly to different amounts of thimerosal through immunization. METHODS. Children who were enrolled in an efficacy trial of pertussis vaccines in 1992–1993 were contacted in 2003. Two groups of children were identified, according to thimerosal content in vaccines assigned randomly in the first year of life (cumulative ethylmercury intake of 62.5 or 137.5 μg), and were compared with respect to neuropsychological outcome…

MalePediatricsmedicine.medical_specialtyTime FactorsEthylmercury compoundTime FactorDevelopmental DisabilitiesDevelopmental DisabilitieControlled trialRandomizedNeuropsychological Testslaw.inventionchemistry.chemical_compoundEthylmercurySettore MED/38 - Pediatria Generale E SpecialisticaRandomized controlled triallawHumansMedicineNeuropsychological assessmentChildVaccinesmedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicabusiness.industryThimerosalPreservatives PharmaceuticalInfantThimerosalNeuropsychological testExecutive functionsBoston Naming TestchemistryPediatrics Perinatology and Child HealthImmunizationFemaleNeuropsychological TestThiomersalbusinessVaccineHuman
researchProduct

In vitro evaluation of glycol chitosan based formulations as oral delivery systems for efflux pump inhibition.

2017

Recently, we have reported that glycol chitosan (GCS) was able to reverse the P- glycoprotein (P-gp) efflux pump. The objective of the present study was to evaluate the potential of two GCS-based dosage forms (aqueous solution or nanoparticle suspension) for oral administration of the P-gp substrate Rho-123. A further aim of the present study was to assess the effect of the glycol chitosan-4-thiobutylamidine thiomer (GCS-TBA) on P-gp activity considering that the corresponding thiomer of chitosan series is a well-known P-gp inhibitor. Pre-treatment of Caco-2 cell monolayer with a GCS solution or GCS-based nanoparticles increased the absorptive transport of Rho-123 across the monolayer of 1.…

endocrine systemATP Binding Cassette Transporter Subfamily BPolymers and Plastics02 engineering and technologyPharmacologyDosage formChitosan03 medical and health scienceschemistry.chemical_compoundGlycols0302 clinical medicineDrug Delivery SystemsOral administrationhealth services administrationpolycyclic compoundsMaterials ChemistryHumansGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailabilityChitosanChemistryThiomerOrganic ChemistryGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailability021001 nanoscience & nanotechnologyBioavailabilityCaco-2Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisNanoparticlessense organsEffluxCaco-2 Cells0210 nano-technologyhormones hormone substitutes and hormone antagonistsConjugateCarbohydrate polymers
researchProduct